Active, not recruitingPhase 2NCT02180724
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Studying Waldenström Macroglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Acerta Pharma BV
- Principal Investigator
- AstraZeneca Clinical study Information Center1-877-240-9479 information.center@astrazeneca.com
- Intervention
- Acalabrutinib (ACP-196)(drug)
- Enrollment
- 107 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2026
Study locations (30)
- Research Site, Santa Barbara, California, United States
- Research Site, Aurora, Colorado, United States
- Research Site, Washington D.C., District of Columbia, United States
- Research Site, Minneapolis, Minnesota, United States
- Research Site, New York, New York, United States
- Research Site, Nashville, Tennessee, United States
- Research Site, Austin, Texas, United States
- Research Site, Bedford, Texas, United States
- Research Site, Houston, Texas, United States
- Research Site, Vancouver, Washington, United States
- Research Site, Aurillac, France
- Research Site, Clermond Ferrand, France
- Research Site, Marseille, France
- Research Site, Montpellier, France
- Research Site, Nantes, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02180724 on ClinicalTrials.govOther trials for Waldenström Macroglobulinemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07471074Phenotypic and Functional Study of Bone Marrow Mesenchymal Stem Cells in Waldenström MacroglobulinemiaCentre Hospitalier Universitaire, Amiens
- RECRUITINGPHASE2NCT06986174A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaShayna Sarosiek, MD
- RECRUITINGPHASE4NCT07169331A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström MacroglobulinemiaBeiGene
- ACTIVE NOT RECRUITINGPHASE2NCT05952037A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaBeOne Medicines
- RECRUITINGPHASE2NCT05734495Pirtobrutinib and Venetoclax in Waldenström MacroglobulinemiaDana-Farber Cancer Institute
- RECRUITINGNCT05640102Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström MacroglobulinemiaBeiGene
- RECRUITINGNANCT04893564Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström MacroglobulinemiaCentre Hospitalier Universitaire, Amiens
- RECRUITINGNANCT04898647Clinical Study of the Hyperviscosity Syndrome in Waldenström MacroglobulinemiaCentre Hospitalier Universitaire, Amiens